CDXS News and Press, Codexis Inc. From 07/14/22

Codexis ( NASDAQ: CDXS ) on Thursday said it had inked a deal with Pfizer ( PFE ) to make an enzyme used to manufacture nirmatrelvir, which is an active pharmaceutical ingredient in the U.S. drug giant's COVID-19 antiviral pill Paxlovid. In an separate 8-K filing w...

REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the Company has entered into an agreement with Pfizer for the supply of a proprietary high-performance e...

REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced preliminary revenue results for the second quarter ending June 30, 2022 and updated its revenue guidance for ...

Baillie Gifford’s 13F portfolio value decreased from ~$182B to ~$143B this quarter. They increased Affirm Holdings, Coupang, and Ginkgo Bioworks while reducing Petroleo Brasileiro and First Republic Bank. The top three positions are Tesla Motors, Moderna, and Illumina, and ...

Over the past seven weeks, I have suggested that healthcare stocks, and specifically biopharmaceuticals, had begun to bottom. I expected the process to be rocky with an upside bias. As I spoke with sell side analysts, buy side investors and individuals, I found support for my thinking...

Codexis < > along with Merck (NYSE:MRK) announced the development of a suite of enzymes and their application for site-selective synthesis of insulin bioconjugates. The data were published in journal Science. The publication describes the development and optimization of enzy...

Collaboration with Merck published in Science magazine REDWOOD CITY, Calif., June 17, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announces the publication with Merck, known as MSD o...

REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in two upcoming investor conferences. The UBS Global Healthcare Co...

REDWOOD CITY, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that three of its gene therapy programs are the subject of two poster presentations at the American Society ...

The following slide deck was published by Codexis, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Codexis, Inc. 2022 Q1 - Results - Earnings Call Presentation